Abstract

Population-based allele frequencies and genotype prevalence are important for measuring the contribution of genetic variation to human disease susceptibility, progression, and outcomes. Population-based prevalence estimates also provide the basis for epidemiologic studies of gene–disease associations, for estimating population attributable risk, and for informing health policy and clinical and public health practice. However, such prevalence estimates for genotypes important to public health remain undetermined for the major racial and ethnic groups in the US population. DNA was collected from 7,159 participants aged 12 years or older in Phase 2 (1991–1994) of the Third National Health and Nutrition Examination Survey (NHANES III). Certain age and minority groups were oversampled in this weighted, population-based US survey. Estimates of allele frequency and genotype prevalence for 90 variants in 50 genes chosen for their potential public health significance were calculated by age, sex, and race/ethnicity among non-Hispanic whites, non-Hispanic blacks, and Mexican Americans. These nationally representative data on allele frequency and genotype prevalence provide a valuable resource for future epidemiologic studies in public health in the United States.

Completion of the human genome sequence (1–3) and recent advances in the analysis of genome-wide associations for several common diseases (4–20) are generating tremendous opportunities for epidemiologic studies to evaluate the role of genetic variants in the etiology of common human diseases. Identification of allelic variants has accelerated as a result of the cataloging and mapping of single nucleotide polymorphisms (SNPs) throughout the genome by the International HapMap Project (21–23) and characterization of the scope of structural variation, including copy number variants, in the genome (24–27). Application of these advances to improve public health requires assessing the frequency of these variants in distinct populations, identifying diseases influenced by these variants, determining the magnitude of the associated risks, and elucidating gene–gene and gene–environment interactions. Although the number of published investigations in these areas of human genome epidemiology has increased rapidly, with publication of more than 6,000 reports yearly (28), methodological issues have made it difficult to integrate the evidence and, thus, to easily translate the findings into public health improvements (29–31).

Early studies of genotype prevalence used samples that were convenient to obtain, and minimal information was provided on the selection of participants (31). In addition, most estimates were calculated from data on small study populations, which limited the accuracy of estimates of allele frequency and genotype prevalence. Furthermore, frequencies for most genetic polymorphisms have been measured only in select US racial and ethnic groups and have not been presented by age group or by sex. Although select polymorphism frequencies have been reported in large populations (32, 33), these studies were community based or controls from larger case-control studies. In contrast, data on genetic variants can be obtained from large, well-designed, epidemiologically well-characterized, and population-based US surveys such as the Third National Health and Nutrition Examination Survey (NHANES III) (34, 35). These data are a unique and unparalleled resource for epidemiologic research to assess genetic variation in the population, gene–disease associations, interactions between gene–gene and gene–environment factors, and population-attributable risk for genetic variants.

In particular, NHANES III offers the opportunity to assess genetic variation among major racial and ethnic groups in the United States, for whom multiple health disparities exist (36–40). Health disparities result from the complex interactions of social, environmental, behavioral, and genetic influences in a diverse population (36, 41, 42). Public health strategies to address health disparities are more likely to be effective when they are based on sound integration of such risk information at the population level. NHANES III is a paradigm for complex analysis of unbiased, population-based data on social, environmental, behavioral, and biologic characteristics—including genetic variation—in relation to health status.

MATERIALS AND METHODS

Survey design

NHANES III is a complex, multistage sample survey conducted by the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC) (35, 43), during 1988–1994. This cross-sectional study was designed to provide national statistics on the health and nutritional status of the civilian, noninstitutionalized population in the United States aged 2 months or older. Certain populations, including young children, older adults, non-Hispanic blacks, and Mexican Americans, were oversampled (35). As with standard NHANES analyses, race/ethnic groups were defined on the basis of the combination of the reported race (black, white, other) and reported ethnicity (not Hispanic, Mexican American, other Hispanic) of survey participants (35). Detailed household interviews were conducted to obtain information on sociodemographic variables, medical history, health-related behaviors, and use of medications. As part of the survey, physical examinations and laboratory and radiologic measurements were performed in special mobile examination centers (35).

NHANES III DNA bank

During Phase 2 of NHANES III (1991–1994), 10,052 participants aged 12 years or older were examined in the mobile examination centers. As part of the examination consent, participants agreed that their blood could be kept for long-term storage and future research, although genetic research was not mentioned specifically. In August 2001, the CDC/NCHS Ethics Review Board approved a revised plan for use of these specimens according to guidelines in the August 1999 National Bioethics Advisory Commission report on the use of stored biologic materials for research. This revised plan allows linkage of the genetic laboratory results to NHANES data through the NCHS Research Data Center to ensure that confidentiality of the study participants’ identities is maintained (44). Attempts were made to establish Epstein-Barr virus-transformed cell lines (35, 44) from white blood cells obtained from 8,200 of the Phase 2 participants. However, the final NHANES III DNA bank contains 7,159 participants because of the inability to transform and grow a successful immortalized cell line (n = 1,004), concerns regarding laboratory practice and quality assurance (n = 21), and exclusion of 16 individuals who were not genotyped. The bank is jointly maintained by both NCHS and the National Center for Environmental Health at CDC. Demographic characteristics of participants in the DNA bank are included in Table 1. Sixty-two percent of participants were from households with multiple family members (average, 1.59 members per household; range, 1–11). This prevalence study was approved by the NCHS Ethics Review Board.

Table 1.

Demographic Characteristics of Participants, Third National Health and Nutrition Examination Survey, Phase 2 (1991–1994), DNA Bank

Demographic Characteristics All Participants
 
Non-Hispanic White
 
Non-Hispanic Black
 
Mexican American
 
Other
 
No. of Subjects Unweighted, % Weighted, % No. of Subjects Unweighted, % Weighted, % No. of Subjects Unweighted, % Weighted, % No. of Subjects Unweighted, % Weighted, % No. of Subjects Unweighted, % Weighted, % 
Total 7,159 100 100 2,630 36.7 73.5 2,108 29.5 11.7 2,073 29.0 5.7 348 4.9 9.2 
Sex                
    Male 3,102 43.3 48.1 1,052 40.0 48.6 897 42.6 45.2 1,024 49.4 51.2 129 37.1 46.2 
    Female 4,057 56.7 51.9 1,578 60.0 51.4 1,211 57.4 54.8 1,049 50.6 48.8 219 62.9 53.8 
Age, years                
    12–19 1,211 16.9 13.6 266 10.1 12.0 483 22.9 18.2 393 19.0 20.1 69 19.8 16.4 
    20–39 2,597 36.3 39.3 709 27.0 37.1 861 40.8 42.9 892 43.0 50.1 135 38.8 45.5 
    40–59 1,552 21.7 27.7 600 22.8 29.0 469 22.2 24.8 403 19.4 21.6 80 23.0 24.6 
    ≥60 1,799 25.1 19.4 1,055 40.1 21.9 295 14.0 14.0 385 18.6 8.2 64 18.4 13.5 
Demographic Characteristics All Participants
 
Non-Hispanic White
 
Non-Hispanic Black
 
Mexican American
 
Other
 
No. of Subjects Unweighted, % Weighted, % No. of Subjects Unweighted, % Weighted, % No. of Subjects Unweighted, % Weighted, % No. of Subjects Unweighted, % Weighted, % No. of Subjects Unweighted, % Weighted, % 
Total 7,159 100 100 2,630 36.7 73.5 2,108 29.5 11.7 2,073 29.0 5.7 348 4.9 9.2 
Sex                
    Male 3,102 43.3 48.1 1,052 40.0 48.6 897 42.6 45.2 1,024 49.4 51.2 129 37.1 46.2 
    Female 4,057 56.7 51.9 1,578 60.0 51.4 1,211 57.4 54.8 1,049 50.6 48.8 219 62.9 53.8 
Age, years                
    12–19 1,211 16.9 13.6 266 10.1 12.0 483 22.9 18.2 393 19.0 20.1 69 19.8 16.4 
    20–39 2,597 36.3 39.3 709 27.0 37.1 861 40.8 42.9 892 43.0 50.1 135 38.8 45.5 
    40–59 1,552 21.7 27.7 600 22.8 29.0 469 22.2 24.8 403 19.4 21.6 80 23.0 24.6 
    ≥60 1,799 25.1 19.4 1,055 40.1 21.9 295 14.0 14.0 385 18.6 8.2 64 18.4 13.5 

Selection of candidate genes and variants

Members from a multidisciplinary working group reviewed available phenotype data from NHANES III, performed systematic literature reviews, and identified candidate genes and physiologic pathways thought to be associated with diseases of public health significance at the time of project initiation. The selection of polymorphisms for this study was also based upon input from the SNP500Cancer resource (45), which had already developed genotyping assays for numerous SNPs in the selected genes based on their potential importance to physiologic processes, epidemiologic studies, and health outcomes.

The selected variants are in genes that encode proteins in 6 major cellular and physiologic pathways: 1) nutrient metabolism (e.g., homocysteine, lipids, glucose, and alcohol); 2) immune and inflammatory responses; 3) xenobiotic metabolism (e.g., of drugs, carcinogens, or environmental contaminants); 4) DNA repair; 5) hemostasis and the renin-angiotensin-aldosterone system; and 6) oxidative stress. The variants are in pathways affecting the development of multiple diseases, including cardiovascular disease, diabetes, cancer, and infectious diseases, as well as modulation of the effects of environmental and occupational exposures.

Genotyping methods

DNA analysis for the project was performed at two facilities because neither lab had methodology developed to analyze all of the genetic variants: 1) the Core Genotyping Facility, National Cancer Institute (NCI), National Institutes of Health, Bethesda, Maryland (http://cgf.nci.nih.gov), and 2) the Division of Laboratory Sciences, National Center for Environmental Health, CDC, Atlanta, Georgia. Each lab analyzed all DNA specimens for each subset of genotyping assays performed.

Most polymorphisms were assayed by either the TaqMan assay (5′ nuclease assay; Applied Biosystems, Foster City, California) or the MGB Eclipse assay (3′ hybridization-triggered fluorescence reaction; Nanogen (formerly Epoch Biosciences), Bothell, Washington). Two polymorphisms were genotyped by pyrosequencing, and one was by capillary fragment analysis. Water controls and DNA samples with known genotypes, purchased from Coriell Cell Repositories (Camden, New Jersey), were included on each 384-well plate. Detailed genotyping methods, including primer and probe sequences, are described in Web Appendix 1 and Web Table 1, respectively. (This information is described in Web-only material that includes 8 Web appendixes, 1 Web table, and 1 Web figure; each is preceded by “Web” in the text. All are posted on the Journal’s website (http://aje.oxfordjournals.org/).)

Quality control

The NHANES III genotyping data were monitored by a quality assurance and quality control committee composed of experts in laboratory science at CDC and NCI. The group monitored results of NHANES III quality control genotyping to ensure that the data met quality control guidelines established by NCHS.

Initial quality assurance assessments determined that at least 7,128 specimens, depending on the laboratory, were suitable for genotyping analysis on the basis of sample quality. All polymorphisms with genotyping call rates below 95% completion did not meet quality control criteria and were removed from further analyses. NHANES provides 480 quality control specimens for all studies that use the NHANES III DNA bank samples. These include blind replicates of approximately 6% of the 7,159 samples, to determine the accuracy and reproducibility of the assays. Assays that passed the blind-replicate analyses (>98% concordance according to NCHS guidelines) were tested for deviation from Hardy-Weinberg proportions calculated separately for each race/ethnic group in a standard unweighted analysis (46). The threshold for a genetic variant to pass Hardy-Weinberg analysis was P ≥ 0.01 (2 sided) for at least 2 of the 3 main race/ethnic groups (i.e., non-Hispanic white, non-Hispanic black, and Mexican American), with use of a chi-square goodness-of-fit test. The race/ethnicity category “other” was not used in determining the deviation from Hardy-Weinberg proportions because of the genetic heterogeneity of this group. Data from 192 samples were removed from certain assays because of a sample handling issue discovered in one of the laboratories. Genetic variants that met all quality control guidelines were used for further analyses. The range of successful genotype identifications for these variants was 97.5%–99.9% (median, 99.2%). Results from the tests of deviations from Hardy-Weinberg proportions for these variants are listed in Web Appendix 2.

Overall, 90 variants in 50 genes were available for estimation of allele frequency and genotype prevalence. Nearly all (n = 87) of the variants genotyped are SNPs, and 3 are insertion/deletions. Various diseases or conditions for which these genes have a confirmed or purported association are shown in Web Appendix 3. This list is not comprehensive, but it demonstrates that the genes studied are involved in major pathways that have a role in the etiology of several diseases or conditions with public health significance.

Statistical analysis

Sample weights.

Because NHANES III is a multistage, complex sample survey, all statistical analyses must account for sample weights and the survey design to produce unbiased national estimates and appropriate standard errors. The variance in clustered data caused by households with multiple related study participants was accounted for by use of the appropriate sample weights and the survey design in SUDAAN software (SUDAAN Statistical Software Center, Research Triangle Park, North Carolina). Point estimates and variances were calculated by using sample weights recalculated (47) for the Genetic Component of NHANES III. These weights were derived from the appropriate NHANES III, Phase 2, mobile examination center (MEC) sample weights to adjust for participant refusal to consent to future research and from the inability to generate cell lines and obtain DNA as mentioned above. NHANES genetic weights are specifically estimated for the genetic component of the 7,159 DNA bank participants, and none of the other weights provided by NHANES is appropriate. More detailed information about statistical weights in NHANES III is available online (http://www.cdc.gov/nchs/about/major/nhanes/nh3data_genetic.htm).

Prevalence estimation.

Analyses were conducted by using SAS-callable SUDAAN, version 9.01, and SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina). Deviations from Hardy-Weinberg proportions were tested with a chi-square goodness-of-fit approach by using SAS/Genetics (SAS Institute, Inc.). Allele frequency and genotype prevalence were calculated in SUDAAN and weighted by using the NHANES III Genetic Component sample weights for each gene variant for all major race/ethnic groups (i.e., non-Hispanic white, non-Hispanic black, Mexican American, and other) (data for “other” are not shown), age groups, and sexes. Point estimates and 95% confidence intervals were calculated and weighted for each race/ethnic group in SUDAAN to obtain the nationally representative estimates for the US population. The Taylor series linearization approach (48, 49), which derives a linear approximation of variance estimates to develop corrected standard errors and confidence intervals, was implemented to estimate variances. Tests of the difference in allele frequencies among race/ethnic groups (“other” was excluded), age groups, and sexes were performed by using polytomous logistic regression. Tests of the differences in genotype prevalence among these groups were evaluated using the Wald chi-square method. Statistical significance was considered as P < 0.05. The differences in allele frequency and genotype prevalence by age and by sex were examined after adjustment for race/ethnicity by using the Cochrane-Mantel-Haenszel test at a significance level of 0.05.

RESULTS

Demographic characteristics of the 7,159 participants in the NHANES III DNA bank are described in Table 1. After adjustment for the NHANES III sample design and for nonresponse in the genetic component, there were slightly more women than men in the US population between 1991 and 1994. The weighted frequency for each of the 3 main race/ethnic groups was 73.5% non-Hispanic white, 11.7% non-Hispanic black, and 5.7% Mexican American. The highest weighted frequency of persons aged 60 or more years and the lowest weighted frequency of persons aged 12–19 years were observed in non-Hispanic whites.

Weighted allele frequency point estimates for the 90 genetic variants for each of the 3 major race/ethnic subgroups in the US population are shown in Table 2. Complete frequency estimates with confidence intervals are shown in Web Figure 1 and Web Appendix 4. Allele frequencies were significantly different across race/ethnic groups for 88 (97.8%) of the variants studied (P < 0.05, two tailed), except for rs4986893 (CYP2C19, no homozygotes for minor allele) and rs1801274 (FCGR2A). Summary allele frequencies among the three major race/ethnic groups are shown in Table 3. Of the 90 candidate gene variants, 80 (88.9%) among non-Hispanic whites, 79 (87.8%) among non-Hispanic blacks, and 80 (88.9%) among Mexican Americans had allele frequencies of 0.02 or greater.

Table 2.

Weighted Allele Frequencies of Genetic Variants in the US Population by Race/Ethnicity, Third National Health and Nutrition Examination Survey, Phase 2 (1991–1994), DNA Bank

Gene Symbola Gene Name [Chromosomal Position]a Pathwayb Variantc Nucleotide Position [Amino Acid Change]d Allelee Total US, %f Non-Hispanic White, % Non-Hispanic Black, % Mexican American, % P Valueg 
ABCB1 ATP-binding cassette, subfamily B (MDR/TAP), member 1 [7q21.1] 13 rs1045642 Ex27-55; 3435 [I1145I] T (C) 47.3 51.6 20.9 44.7 <0.001 
ACE Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 [17q23.3] 2, 12 rs4646994 289-bp Alu ins/del in intron 16 ins (del) 46.2 45.4 41.3 53.4 <0.001 
ADH1B Alcohol dehydrogenase IB (class I), beta polypeptide [4q21-q23] 12, 13 rs1229984 Ex3 + 23 [R48H] A (G) 6.4 4.7 1.4 5.5 <0.001 
rs17033 Ex9 + 77 G (A) 10.0 8.5 6.9 30.0 <0.001 
rs2066702 Ex9 + 5 [R370C] T (C) 2.9 0.4 20.0 0.9 <0.001 
ADH1C Alcohol dehydrogenase 1C (class I), gamma polypeptide [4q21-q23] 12, 13 rs1693482 Ex6-14 [R272Q] A (G) 33.8 38.5 14.6 34.1 <0.001 
rs698 Ex8-56 [I350V] G (A) 34.4 39.4 14.9 31.1h <0.001 
ADRB1 Adrenergic, beta-1-, receptor [10q24-q26] 2, 3, 12 rs1801252 Ex1 + 231 [S49G] G (A) 15.7 13.2 22.5 28.0 <0.001 
ADRB2 Adrenergic, beta-2-, receptor, surface [5q31-q32] 2, 3, 12 rs1042713 Ex1 + 265 [G16R] A (G) 40.5 38.9 49.7 41.8 <0.001 
rs1042714 Ex1 + 298 [E27Q] G (C) 36.0 41.9 18.0 21.3 <0.001 
ADRB3 Adrenergic, beta-3-, receptor [8p12-p11.2] 12 rs4994 Ex1 + 387 [W64R] C (T) 8.6 6.9 11.7 16.6 <0.001 
ALAD Aminolevulinate, delta-, dehydratase [9q33.1] 12, 13 rs1800435 Ex4 + 13; 177 [K68N; K88N] C (G) 6.5 8.1 1.3 4.5 <0.001 
B9D2B9 protein domain 2 [19q13.2] 14 rs1800468 Ex4-262; −800 of TGFB1 A (G) 6.7 7.6 2.8 4.6 <0.001 
rs1800469 308 bp 3′ of STP; −509 of TGFB1 T (C) 32.1 31.4 23.8 44.8 <0.001 
CAPN10 Calpain 10 [2q37.3] 1, 12 rs3792267 IVS3-176 A (G) 24.6 25.8 16.2 27.3 <0.001 
CAT Catalase [11p13] 11, 12 rs769214 −843 G (A) 37.6 33.9 41.2 50.3 <0.001 
CBS Cystathionine-beta-synthase [21q22.3] 12 No rs number 844ins68 (68-bp insertion in exon 8) + (−) 10.0 8.1 25.9 6.3 <0.001 
CCL5 Chemokine (C-C motif) ligand 5 [17q11.2-q12] 5, 10 rs2280788 −95 G (C) 2.6 2.8 0.7 1.3 <0.001 
CCR2 Chemokine (C-C motif) receptor 2 [3p21.31] 5, 10 rs1799864 Ex2 + 241 [V64I] A (G) 11.2 9.5 14.5 21.7 <0.001 
CXCL12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) [10q11.1] 5, 10 rs169097 Ex5 + 709 T (C) 2.5 0.3h 17.2 1.0 <0.001 
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 [15q22-q24] 12, 13 rs2472299 −17961 T (C) 29.8 28.2 38.5 26.7 <0.001 
rs2606345 IVS1 + 606 G (T) 44.0 33.8 84.1 61.7 <0.001 
CYP1A2 Cytochrome P450, family 1, subfamily A, polypeptide 2 [15q24] 12, 13 rs11854147 5341 bp 3′ of STP T (C) 40.4 31.4h 72.1 61.3 <0.001 
rs2069514 −3859 A (G) 8.4 1.6 26.3 33.7 <0.001 
rs4886406 9773 bp 3′ of STP G (T) 29.4 27.8 38.3 26.5 <0.001 
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 [2p21] 12, 13 rs1056836 Ex3 + 251 [V432L] G (C) 46.0 45.2 75.0 26.5 <0.001 
rs1056837 Ex3 + 304 [D449D] T (C) 45.5 45.0 72.7 26.3 <0.001 
rs162557 −2919 T (C) 21.4 23.2 21.6 13.1 <0.001 
CYP2A6 Cytochrome P450, family 2, subfamily A, polypeptide 6 [19q13.2] 12, 13 rs1801272 Ex3-15 [L160H] A (T) 2.7 3.3 0.6 2.0 <0.001 
CYP2C19 Cytochrome P450, family 2, subfamily C, polypeptide 19 [10q24.1-q24.3] 12, 13 rs4986893 Ex4-7 [W212*] A (G) 0.2 0.1 0.2 0.1 0.744 
rs4986894 −97 C (T) 14.8 13.7 18.3 11.0 <0.001 
CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 9 [10q24] 12, 13 rs1057910 Ex7-75 [I359L] C (A) 5.8 6.8 1.1 3.9 <0.001 
CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 [10q24.3-qter] 12, 13 rs2031920 −1054; −1053 T (C) 3.1 2.2 0.8 10.7 <0.001 
CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4 [7q21.1] 12, 13 rs2740574 −391 G (A) 11.7 4.1 64.0 7.7 <0.001 
F2 Coagulation factor II (thrombin) [11p11-q12] 5, 9 rs1799963 Ex14-1 A (G) 1.0 1.1 0.3 1.1 0.001 
F5 Coagulation factor V (proaccelerin, labile factor) [1q23] rs6025 Ex10-11 [R534Q] A (G) 2.2 2.6 0.6 1.0 <0.001 
FAM82AFamily with sequence similarity 82, member A [2p22.2] 14 rs163086 IVS10-1363 T (C) 21.3 22.8 19.1 14.5 <0.001 
FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) [1q23] 10 rs1801274 Ex4−120 [H166R; H167R] A (G) 50.0 49.4 47.4 48.6 0.096 
FGB Fibrinogen beta chain [4q28] 6, 9 rs1800790 −462 A (G) 17.6 19.4 5.5 15.0 <0.001 
IL10 Interleukin 10 [1q31-q32] 1, 4, 7, 10 rs1800871 −853; −819 T (C) 29.0 24.2 39.6 38.1 <0.001 
rs1800872 −626; −592 A (C) 29.0 24.3 39.3 37.9 <0.001 
rs1800896 −1116; −1082 G (A) 42.3 46.9 35.6 30.5 <0.001 
IL1B Interleukin 1, beta [2q14] 1, 7, 10 rs1143623 −2022 C (G) 28.7 28.5 11.2 42.9 <0.001 
IL4 Interleukin 4 [5q31.1] 1, 7, 10 rs2243248 −1098 G (T) 9.0 7.5 15.7 12.0 <0.001 
rs2243250 −588; −524; −590 T (C) 25.5 16.0 64.0 42.3 <0.001 
rs2243270 IVS2-1297 G (A) 25.7 16.4 63.7 41.8 <0.001 
IL4R Interleukin 4 receptor [16p11.2-12.1] 1, 7, 10 rs1801275 Ex12 + 828 [Q576R] G (A) 26.8 20.8 67.1h 28.6 <0.001 
rs1805015 Ex12 + 608 [S503P] C (T) 17.8 15.7 36.7 15.7 <0.001 
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) [5q23-q31] 5, 6, 9 rs1126643 Ex7-21 [F253F] T (C) 39.7 41.2 29.6 44.6 <0.001 
ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) [17q21.32] 1, 5, 6, 9 rs5918 Ex3 + 11 [L59P] C (T) 14.4 16.3 10.1 9.7 <0.001 
MBL2 Mannose-binding lectin (protein C) 2, soluble (opsonic defect) [10q11.2-q21] 10 rs11003125 −618; −550 G (C) 34.9 36.4 12.8 51.0 <0.001 
rs1800450 Ex1-27 [G54D] A(G) 13.5 14.6 4.0 14.6 <0.001 
rs1800451 Ex1-18 [G57E] A (G) 4.6 2.0 23.3 2.5 <0.001 
rs5030737 Ex1-34 [R52C] T (C) 6.1 7.4 1.1 2.9h <0.001 
rs7096206 −289; −221 C (G) 20.4 22.4 15.1 11.4h <0.001 
MTHFR 5,10-Methylenetetrahydrofolate reductase (NADPH) [1p36.3] 12 rs1801131 Ex8-62; 1298 [E429A] C (A) 28.4 31.1 17.9 18.8 <0.001 
rs1801133 Ex5 + 79; 677 [A222V] T (C) 30.8 32.6 11.6 44.6 <0.001 
rs2066470 Ex2-120 [P39P] T (C) 9.7 9.6 8.7 6.5 0.042 
MTRR 5-Methyltetrahydrofolate-homocysteine methyltransferase reductase [5p15.3-p15.2] 12 rs1801394 Ex2-64 [I22M; I49M] G (A) 46.9 52.8 28.7 26.1 <0.001 
NAT2 N-Acetyltransferase 2 (arylamine N-acetyltransferase) [8p22] 13 rs1041983 Ex2 + 288 [Y94Y] T (C) 36.4 35.4 46.1 31.9 <0.001 
rs1208 Ex2-367 [K268R] G (A) 39.4 41.0 38.3 35.7 <0.001 
rs1799930 Ex2-580 [R197Q] A (G) 30.2 32.3 28.0 18.0 <0.001 
rs1801279 Ex2 + 197 [R64Q] A (G) 1.0 0.0 7.8 0.5h <0.001 
rs1801280 Ex2 + 347 [I114T] C (T) 38.9 42.1 29.3 32.4 <0.001 
NOS2A Nitric oxide synthase 2A (inducible, hepatocytes) [17q11.2-q12] 2, 10, 11, 12 rs1800482 G>C in promoter C (G) 1.0 0.1 6.3 0.3h <0.001 
rs9282799 −2892; −1173 T (C) 0.7 0.0 4.5 0.4 <0.001 
NOS3 Nitric oxide synthase 3 (endothelial cell) [7q36] 2, 3, 9, 11, 12 rs1799983 Ex8-63 [E298D] T (G) 28.5 32.5 13.1 19.6 <0.001 
rs2070744 IVS1-762; −786 C (T) 34.2 39.1 15.1 25.1 <0.001 
NQO1 NAD(P)H dehydrogenase, quinone 1 [16q22.1] 12, 13 rs10517 Ex6-457 T (C) 13.6 13.2 13.9 6.5 <0.001 
rs1800566 Ex6 + 40; 609 [P187S; P149S; P153S] T (C) 21.5 19.4 18.8 36.8 <0.001 
rs34755915 IVS3 + 20 A (G) 1.4 1.8 0.4 0.5 <0.001 
rs689452 IVS1-27 G (C) 12.5 11.9 13.7 6.3 <0.001 
rs689453 Ex2 + 65 [E24E] A (G) 7.0 7.9 5.1 5.2 <0.001 
OGG1 8-Oxoguanine DNA glycosylase [3p26.2] rs1052133 Ex6-315 [S326C; P332A] G (C) 23.0 21.5 16.4 33.0 <0.001 
PON1 Paraoxonase 1 [7q21.3] 11, 13 rs662 Ex6 + 78 [Q192R] G (A) 38.5 31.5 67.1 46.5 <0.001 
rs854560 Ex3 + 18 [L55M] A (T) 31.5 35.6 17.9 23.0 <0.001 
PPARG Peroxisome proliferator-activated receptor gamma [3p25] 7, 10, 12 rs1801282 Ex4-49 [P12A] G (C) 11.6 13.2 2.5 12.4 <0.001 
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 [7q21.3-q22] 5, 6, 9, 12 rs1799762, rs1799768, rs1799889 4G/5G ins/del in promoter 4G (5G) 47.9 52.5 26.7 34.0 <0.001 
TGFB1 Transforming growth factor, beta 1 [19q13.1] 1, 4, 7, 10 rs1982073 Ex1-327 [P10L] C (T) 40.4 38.5 44.0 50.3 <0.001 
TLR4 Toll-like receptor 4 [9q32-q33] 10 rs4986790 Ex4 + 636 [D299G] G (A) 6.4 6.8 7.5 2.5 <0.001 
TNF Tumor necrosis factor (TNF superfamily, member 2) [6p21.3] 1, 4, 7, 10, 12 rs1800629 −487; −308 A (G) 15.3 17.2 13.1 7.3 <0.001 
rs1800750 −555 A (G) 1.6 1.3h 2.3 2.5 0.07 
rs361525 −417; −238 A (G) 5.5 5.8 4.1 5.8 0.05 
VDR Vitamin D (1,25- dihydroxyvitamin D3) receptor [12q13.11] 7, 10, 12 rs2239185 IVS8-3968 C (T) 49.3 47.8h 42.9 58.2 <0.001 
rs731236 Ex11 + 32 [I352I (TaqI variant)] C (T) 34.5 38.1 28.2 23.8 <0.001 
XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 [19q13.2] rs1001581 IVS2-216 A (G) 38.9 39.9 36.7 30.2 <0.001 
rs1799782 Ex6-22 [R194W] T (C) 7.0 5.0 6.2 14.8 <0.001 
rs25486 IVS9-59 G (A) 33.6 36.0 24.1 25.8 <0.001 
rs25487 Ex10-4 [R399Q] A (G) 32.6 36.1 15.9 25.6 <0.001 
rs25489 Ex9 + 16 [R280H] A (G) 4.7 4.0 3.5 12.4 <0.001 
Gene Symbola Gene Name [Chromosomal Position]a Pathwayb Variantc Nucleotide Position [Amino Acid Change]d Allelee Total US, %f Non-Hispanic White, % Non-Hispanic Black, % Mexican American, % P Valueg 
ABCB1 ATP-binding cassette, subfamily B (MDR/TAP), member 1 [7q21.1] 13 rs1045642 Ex27-55; 3435 [I1145I] T (C) 47.3 51.6 20.9 44.7 <0.001 
ACE Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 [17q23.3] 2, 12 rs4646994 289-bp Alu ins/del in intron 16 ins (del) 46.2 45.4 41.3 53.4 <0.001 
ADH1B Alcohol dehydrogenase IB (class I), beta polypeptide [4q21-q23] 12, 13 rs1229984 Ex3 + 23 [R48H] A (G) 6.4 4.7 1.4 5.5 <0.001 
rs17033 Ex9 + 77 G (A) 10.0 8.5 6.9 30.0 <0.001 
rs2066702 Ex9 + 5 [R370C] T (C) 2.9 0.4 20.0 0.9 <0.001 
ADH1C Alcohol dehydrogenase 1C (class I), gamma polypeptide [4q21-q23] 12, 13 rs1693482 Ex6-14 [R272Q] A (G) 33.8 38.5 14.6 34.1 <0.001 
rs698 Ex8-56 [I350V] G (A) 34.4 39.4 14.9 31.1h <0.001 
ADRB1 Adrenergic, beta-1-, receptor [10q24-q26] 2, 3, 12 rs1801252 Ex1 + 231 [S49G] G (A) 15.7 13.2 22.5 28.0 <0.001 
ADRB2 Adrenergic, beta-2-, receptor, surface [5q31-q32] 2, 3, 12 rs1042713 Ex1 + 265 [G16R] A (G) 40.5 38.9 49.7 41.8 <0.001 
rs1042714 Ex1 + 298 [E27Q] G (C) 36.0 41.9 18.0 21.3 <0.001 
ADRB3 Adrenergic, beta-3-, receptor [8p12-p11.2] 12 rs4994 Ex1 + 387 [W64R] C (T) 8.6 6.9 11.7 16.6 <0.001 
ALAD Aminolevulinate, delta-, dehydratase [9q33.1] 12, 13 rs1800435 Ex4 + 13; 177 [K68N; K88N] C (G) 6.5 8.1 1.3 4.5 <0.001 
B9D2B9 protein domain 2 [19q13.2] 14 rs1800468 Ex4-262; −800 of TGFB1 A (G) 6.7 7.6 2.8 4.6 <0.001 
rs1800469 308 bp 3′ of STP; −509 of TGFB1 T (C) 32.1 31.4 23.8 44.8 <0.001 
CAPN10 Calpain 10 [2q37.3] 1, 12 rs3792267 IVS3-176 A (G) 24.6 25.8 16.2 27.3 <0.001 
CAT Catalase [11p13] 11, 12 rs769214 −843 G (A) 37.6 33.9 41.2 50.3 <0.001 
CBS Cystathionine-beta-synthase [21q22.3] 12 No rs number 844ins68 (68-bp insertion in exon 8) + (−) 10.0 8.1 25.9 6.3 <0.001 
CCL5 Chemokine (C-C motif) ligand 5 [17q11.2-q12] 5, 10 rs2280788 −95 G (C) 2.6 2.8 0.7 1.3 <0.001 
CCR2 Chemokine (C-C motif) receptor 2 [3p21.31] 5, 10 rs1799864 Ex2 + 241 [V64I] A (G) 11.2 9.5 14.5 21.7 <0.001 
CXCL12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) [10q11.1] 5, 10 rs169097 Ex5 + 709 T (C) 2.5 0.3h 17.2 1.0 <0.001 
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 [15q22-q24] 12, 13 rs2472299 −17961 T (C) 29.8 28.2 38.5 26.7 <0.001 
rs2606345 IVS1 + 606 G (T) 44.0 33.8 84.1 61.7 <0.001 
CYP1A2 Cytochrome P450, family 1, subfamily A, polypeptide 2 [15q24] 12, 13 rs11854147 5341 bp 3′ of STP T (C) 40.4 31.4h 72.1 61.3 <0.001 
rs2069514 −3859 A (G) 8.4 1.6 26.3 33.7 <0.001 
rs4886406 9773 bp 3′ of STP G (T) 29.4 27.8 38.3 26.5 <0.001 
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 [2p21] 12, 13 rs1056836 Ex3 + 251 [V432L] G (C) 46.0 45.2 75.0 26.5 <0.001 
rs1056837 Ex3 + 304 [D449D] T (C) 45.5 45.0 72.7 26.3 <0.001 
rs162557 −2919 T (C) 21.4 23.2 21.6 13.1 <0.001 
CYP2A6 Cytochrome P450, family 2, subfamily A, polypeptide 6 [19q13.2] 12, 13 rs1801272 Ex3-15 [L160H] A (T) 2.7 3.3 0.6 2.0 <0.001 
CYP2C19 Cytochrome P450, family 2, subfamily C, polypeptide 19 [10q24.1-q24.3] 12, 13 rs4986893 Ex4-7 [W212*] A (G) 0.2 0.1 0.2 0.1 0.744 
rs4986894 −97 C (T) 14.8 13.7 18.3 11.0 <0.001 
CYP2C9 Cytochrome P450, family 2, subfamily C, polypeptide 9 [10q24] 12, 13 rs1057910 Ex7-75 [I359L] C (A) 5.8 6.8 1.1 3.9 <0.001 
CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 [10q24.3-qter] 12, 13 rs2031920 −1054; −1053 T (C) 3.1 2.2 0.8 10.7 <0.001 
CYP3A4 Cytochrome P450, family 3, subfamily A, polypeptide 4 [7q21.1] 12, 13 rs2740574 −391 G (A) 11.7 4.1 64.0 7.7 <0.001 
F2 Coagulation factor II (thrombin) [11p11-q12] 5, 9 rs1799963 Ex14-1 A (G) 1.0 1.1 0.3 1.1 0.001 
F5 Coagulation factor V (proaccelerin, labile factor) [1q23] rs6025 Ex10-11 [R534Q] A (G) 2.2 2.6 0.6 1.0 <0.001 
FAM82AFamily with sequence similarity 82, member A [2p22.2] 14 rs163086 IVS10-1363 T (C) 21.3 22.8 19.1 14.5 <0.001 
FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) [1q23] 10 rs1801274 Ex4−120 [H166R; H167R] A (G) 50.0 49.4 47.4 48.6 0.096 
FGB Fibrinogen beta chain [4q28] 6, 9 rs1800790 −462 A (G) 17.6 19.4 5.5 15.0 <0.001 
IL10 Interleukin 10 [1q31-q32] 1, 4, 7, 10 rs1800871 −853; −819 T (C) 29.0 24.2 39.6 38.1 <0.001 
rs1800872 −626; −592 A (C) 29.0 24.3 39.3 37.9 <0.001 
rs1800896 −1116; −1082 G (A) 42.3 46.9 35.6 30.5 <0.001 
IL1B Interleukin 1, beta [2q14] 1, 7, 10 rs1143623 −2022 C (G) 28.7 28.5 11.2 42.9 <0.001 
IL4 Interleukin 4 [5q31.1] 1, 7, 10 rs2243248 −1098 G (T) 9.0 7.5 15.7 12.0 <0.001 
rs2243250 −588; −524; −590 T (C) 25.5 16.0 64.0 42.3 <0.001 
rs2243270 IVS2-1297 G (A) 25.7 16.4 63.7 41.8 <0.001 
IL4R Interleukin 4 receptor [16p11.2-12.1] 1, 7, 10 rs1801275 Ex12 + 828 [Q576R] G (A) 26.8 20.8 67.1h 28.6 <0.001 
rs1805015 Ex12 + 608 [S503P] C (T) 17.8 15.7 36.7 15.7 <0.001 
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) [5q23-q31] 5, 6, 9 rs1126643 Ex7-21 [F253F] T (C) 39.7 41.2 29.6 44.6 <0.001 
ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) [17q21.32] 1, 5, 6, 9 rs5918 Ex3 + 11 [L59P] C (T) 14.4 16.3 10.1 9.7 <0.001 
MBL2 Mannose-binding lectin (protein C) 2, soluble (opsonic defect) [10q11.2-q21] 10 rs11003125 −618; −550 G (C) 34.9 36.4 12.8 51.0 <0.001 
rs1800450 Ex1-27 [G54D] A(G) 13.5 14.6 4.0 14.6 <0.001 
rs1800451 Ex1-18 [G57E] A (G) 4.6 2.0 23.3 2.5 <0.001 
rs5030737 Ex1-34 [R52C] T (C) 6.1 7.4 1.1 2.9h <0.001 
rs7096206 −289; −221 C (G) 20.4 22.4 15.1 11.4h <0.001 
MTHFR 5,10-Methylenetetrahydrofolate reductase (NADPH) [1p36.3] 12 rs1801131 Ex8-62; 1298 [E429A] C (A) 28.4 31.1 17.9 18.8 <0.001 
rs1801133 Ex5 + 79; 677 [A222V] T (C) 30.8 32.6 11.6 44.6 <0.001 
rs2066470 Ex2-120 [P39P] T (C) 9.7 9.6 8.7 6.5 0.042 
MTRR 5-Methyltetrahydrofolate-homocysteine methyltransferase reductase [5p15.3-p15.2] 12 rs1801394 Ex2-64 [I22M; I49M] G (A) 46.9 52.8 28.7 26.1 <0.001 
NAT2 N-Acetyltransferase 2 (arylamine N-acetyltransferase) [8p22] 13 rs1041983 Ex2 + 288 [Y94Y] T (C) 36.4 35.4 46.1 31.9 <0.001 
rs1208 Ex2-367 [K268R] G (A) 39.4 41.0 38.3 35.7 <0.001 
rs1799930 Ex2-580 [R197Q] A (G) 30.2 32.3 28.0 18.0 <0.001 
rs1801279 Ex2 + 197 [R64Q] A (G) 1.0 0.0 7.8 0.5h <0.001 
rs1801280 Ex2 + 347 [I114T] C (T) 38.9 42.1 29.3 32.4 <0.001 
NOS2A Nitric oxide synthase 2A (inducible, hepatocytes) [17q11.2-q12] 2, 10, 11, 12 rs1800482 G>C in promoter C (G) 1.0 0.1 6.3 0.3h <0.001 
rs9282799 −2892; −1173 T (C) 0.7 0.0 4.5 0.4 <0.001 
NOS3 Nitric oxide synthase 3 (endothelial cell) [7q36] 2, 3, 9, 11, 12 rs1799983 Ex8-63 [E298D] T (G) 28.5 32.5 13.1 19.6 <0.001 
rs2070744 IVS1-762; −786 C (T) 34.2 39.1 15.1 25.1 <0.001 
NQO1 NAD(P)H dehydrogenase, quinone 1 [16q22.1] 12, 13 rs10517 Ex6-457 T (C) 13.6 13.2 13.9 6.5 <0.001 
rs1800566 Ex6 + 40; 609 [P187S; P149S; P153S] T (C) 21.5 19.4 18.8 36.8 <0.001 
rs34755915 IVS3 + 20 A (G) 1.4 1.8 0.4 0.5 <0.001 
rs689452 IVS1-27 G (C) 12.5 11.9 13.7 6.3 <0.001 
rs689453 Ex2 + 65 [E24E] A (G) 7.0 7.9 5.1 5.2 <0.001 
OGG1 8-Oxoguanine DNA glycosylase [3p26.2] rs1052133 Ex6-315 [S326C; P332A] G (C) 23.0 21.5 16.4 33.0 <0.001 
PON1 Paraoxonase 1 [7q21.3] 11, 13 rs662 Ex6 + 78 [Q192R] G (A) 38.5 31.5 67.1 46.5 <0.001 
rs854560 Ex3 + 18 [L55M] A (T) 31.5 35.6 17.9 23.0 <0.001 
PPARG Peroxisome proliferator-activated receptor gamma [3p25] 7, 10, 12 rs1801282 Ex4-49 [P12A] G (C) 11.6 13.2 2.5 12.4 <0.001 
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 [7q21.3-q22] 5, 6, 9, 12 rs1799762, rs1799768, rs1799889 4G/5G ins/del in promoter 4G (5G) 47.9 52.5 26.7 34.0 <0.001 
TGFB1 Transforming growth factor, beta 1 [19q13.1] 1, 4, 7, 10 rs1982073 Ex1-327 [P10L] C (T) 40.4 38.5 44.0 50.3 <0.001 
TLR4 Toll-like receptor 4 [9q32-q33] 10 rs4986790 Ex4 + 636 [D299G] G (A) 6.4 6.8 7.5 2.5 <0.001 
TNF Tumor necrosis factor (TNF superfamily, member 2) [6p21.3] 1, 4, 7, 10, 12 rs1800629 −487; −308 A (G) 15.3 17.2 13.1 7.3 <0.001 
rs1800750 −555 A (G) 1.6 1.3h 2.3 2.5 0.07 
rs361525 −417; −238 A (G) 5.5 5.8 4.1 5.8 0.05 
VDR Vitamin D (1,25- dihydroxyvitamin D3) receptor [12q13.11] 7, 10, 12 rs2239185 IVS8-3968 C (T) 49.3 47.8h 42.9 58.2 <0.001 
rs731236 Ex11 + 32 [I352I (TaqI variant)] C (T) 34.5 38.1 28.2 23.8 <0.001 
XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 [19q13.2] rs1001581 IVS2-216 A (G) 38.9 39.9 36.7 30.2 <0.001 
rs1799782 Ex6-22 [R194W] T (C) 7.0 5.0 6.2 14.8 <0.001 
rs25486 IVS9-59 G (A) 33.6 36.0 24.1 25.8 <0.001 
rs25487 Ex10-4 [R399Q] A (G) 32.6 36.1 15.9 25.6 <0.001 
rs25489 Ex9 + 16 [R280H] A (G) 4.7 4.0 3.5 12.4 <0.001 

Abbreviations: ATP, adenosine triphosphate; bp, base pair(s); del, deletion; ex, exon; HUGO, Human Genome Organisation; IgG, immunoglobulin G; ins, insertion; IVS, intervening sequence; MDR, multidrug resistance; NADPH, nicotinamide adenine dinucleotide phosphate; rs, reference SNP; SNP, single nucleotide polymorphism; STP, STOP codon; TAP, transporter-associated antigen processing.

a

Official gene symbols and names are from the HUGO Gene Nomenclature Committee (http://www.genenames.org/). All chromosomal positions are from Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/entrez?db = gene).

b

Inclusion of genes in pathways is based on information gathered from the GeneCards database (http://www.genecards.org), the KEGG GENES database (http://www.genome.jp/kegg/genes.html), and selected publications for ACE, CAPN10, and SERPINE1 (refer to references in Web Appendix 3): 1, apoptosis; 2, blood pressure regulation; 3, cardiac function; 4, cell cycle; 5, cell migration/motility; 6, cellular adhesion; 7, cellular growth and differentiation; 8, DNA repair; 9, hemostasis; 10, immunity and inflammation; 11, metabolism of free radicals/oxidative stress; 12, nutrient metabolism; 13, xenobiotic metabolism; 14, unknown.

c

Unique identifier in the Entrez SNP database at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/projects/SNP/).

d

Nucleotide and amino acid change information are from the SNP500Cancer database (http://snp500cancer.nci.nih.gov) and dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/). Alternate designations and additional locus information are given, if available.

e

The major allele (determined by the frequency in the total population) is in parentheses.

f

Includes the “other” race/ethnicity category.

g

The “other” race/ethnicity category was not included in chi-square tests.

h

The variant deviates from Hardy-Weinberg proportions in the race/ethnicity group at P < 0.01 in an unweighted chi-square goodness-of-fit test.

i

B9D2 is a protein that lies partially within the TGFB1 promoter. Although within B9D2, these two SNPs are believed to be promoter polymorphisms of TGFB1.

j

FAM82A is a hypothetical protein that lies immediately 5′ of CYP1B1. This variant may be an intronic polymorphism of FAM82A or a CYP1B1 variant that lies 3′ of the gene.

Table 3.

Range of Allele Frequencies for Study Polymorphisms by Race/Ethnicity, Third National Health and Nutrition Examination Survey, Phase 2 (1991–1994), DNA Bank

Population Allele Frequency
 
0–<0.01
 
0.01–<0.02
 
0.02–<0.05
 
≥0.05
 
No. of Variants With Allele Frequency No. of Variants With Allele Frequency No. of Variants With Allele Frequency No. of Variants With Allele Frequency 
Non-Hispanic white 6.7 4.4 8.9 72 80.0 
Non-Hispanic black 7.8 4.4 7.8 72 80.0 
Mexican American 6.7 4.4 8.9 72 80.0 
Population Allele Frequency
 
0–<0.01
 
0.01–<0.02
 
0.02–<0.05
 
≥0.05
 
No. of Variants With Allele Frequency No. of Variants With Allele Frequency No. of Variants With Allele Frequency No. of Variants With Allele Frequency 
Non-Hispanic white 6.7 4.4 8.9 72 80.0 
Non-Hispanic black 7.8 4.4 7.8 72 80.0 
Mexican American 6.7 4.4 8.9 72 80.0 
Figure 1.

Comparison of minor allele frequencies between the Third National Health and Nutrition Examination Survey (NHANES III), Phase 2 (1991–1994), and other sources. A, T allele of MTHFR rs1801133; B, C allele of VDR rs731236. CI, confidence interval; CUORCGL, Creighton University Osteoporosis Research Center Genetics Lab; EGP-SNPs, National Institute of Environmental Health Sciences Environmental Genome Project; ERASMUS MC, Erasmus University Medical Center; HAPMAP CEPH, International HapMap Project Centre d'Etude du Polymorphisme Humain; rs, reference SNP; SNP, single nucleotide polymorphism; SNP500CANCER, SNP500Cancer database. All data except those for NHANES III have been deposited in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/).

Figure 1.

Comparison of minor allele frequencies between the Third National Health and Nutrition Examination Survey (NHANES III), Phase 2 (1991–1994), and other sources. A, T allele of MTHFR rs1801133; B, C allele of VDR rs731236. CI, confidence interval; CUORCGL, Creighton University Osteoporosis Research Center Genetics Lab; EGP-SNPs, National Institute of Environmental Health Sciences Environmental Genome Project; ERASMUS MC, Erasmus University Medical Center; HAPMAP CEPH, International HapMap Project Centre d'Etude du Polymorphisme Humain; rs, reference SNP; SNP, single nucleotide polymorphism; SNP500CANCER, SNP500Cancer database. All data except those for NHANES III have been deposited in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/).

Differences in minor allele frequency of more than 20% (absolute value) compared with non-Hispanic whites are 22.4% (22 of 90 polymorphisms) for non-Hispanic blacks and 7.8% (2 of 90) for Mexican Americans (data not shown). Comparisons between NHANES III allele frequency estimates and other publicly available data sources are shown in Figure 1, with variants in MTHFR and VDR as examples. As observed, the NHANES III study includes much larger sample sizes, resulting in frequency estimates with small confidence intervals.

Significant differences in genotype prevalence across race/ethnic groups were seen for all variants except three: rs4986893 (CYP2C19), rs1801274 (FCGR2A), and rs2066470 (MTHFR) (Web Appendix 4). Deviations from Hardy-Weinberg proportions were seen for 4 of the 90 polymorphisms (4.4%) among non-Hispanic whites, 1 (1.1%) among non-Hispanic blacks, and 5 (5.6%) among Mexican Americans (P < 0.01) (Web Appendix 2).

Weighted allele and genotype frequencies did not differ significantly by age group in the US population for the majority of the polymorphisms. However, 16 variants (17.8%) differed significantly in allele frequency, and 21 (23.3%) differed significantly in genotype prevalence by age (data not shown). After adjustment for race/ethnicity, these numbers decreased dramatically to 5 (5.6%) polymorphisms for allele frequency (Web Appendix 5) and to 14 (15.6%) variants for genotype prevalence (Web Appendix 6). However, we found that some of the race/ethnicity-adjusted tests may not be reliable because of zero cell counts.

There were no significant differences in allele frequencies or genotype prevalence by sex, except for rs1800451 (MBL2) and rs1800482 (NOS2A) (data not shown). After adjustment for race/ethnicity, the allele frequencies of 3 variants were statistically significant by sex— rs2243248 (IL4), rs1800482 (NOS2A), and rs361525 (TNF) (Web Appendix 7). After adjustment for race/ethnicity, the genotype prevalence of two variants was significantly different between men and women—rs2031920 (CYP2E1) and rs2243248 (IL4) (Web Appendix 8). (All results presented in this study are available online from the website of the National Office of Public Health Genomics at CDC (http://www.cdc.gov/genomics/).)

DISCUSSION

Our study evaluated the allele frequency and genotype prevalence of polymorphisms that have known or proposed associations with common diseases in a large, minority-enriched, and nationally representative sample of the US population. This is the first relatively large-scale, population-based effort in the United States to obtain such data by race/ethnic group. These data and future planned analyses will serve as an important reference for investigations into US population structure, for examinations of gene–disease associations in other investigations of the NHANES data set, for calculation of attributable risk, and for use as a reference by researchers in the design of further studies to discover associations of alleles and genotypes with common diseases.

Estimates of allele frequency and genotype prevalence are available from a number of existing gene variant databases, including the International HapMap Project (21–23) (http://www.hapmap.org) and the SNP500Cancer Database (45) (http://snp500cancer.nci.nih.gov). However, comparisons between NHANES III and such databases are limited because of significant differences in inclusion criteria, study populations, and classification of racial and ethnic groups between NHANES III and the other studies. Especially important is that these public databases function as genomic discovery tools. Consequently, their study populations were drawn largely from a small number of non-population-based samples. These small numbers of participants preclude accurate estimation of allele frequency and genotype prevalence, especially for rare variants or those that vary significantly by race and ethnicity. We compared two variants in MTHFR and VDR with other data resources and found substantial differences in allele frequencies (Figure 1). SNP500Cancer reports the C allele frequency of rs731236 (VDR) as 48.3% (95% confidence interval (CI): 35.3, 61.3) in non-Hispanic whites and as 35.4% (95% CI: 21.4, 49.4) in the African-American population. However, NHANES III estimates are 38.1% (95% CI: 36.0, 40.3) and 28.2% (95% CI: 26.8, 29.6), respectively. In conclusion, the NHANES III estimates of allele frequency and genotype prevalence in the US population are more representative and stable than are those calculated from previously available data.

In this study, allele frequency (in 88 of 90 genetic variants) and genotype prevalence (in 87 of 90 variants) differed significantly by race/ethnic group. Non-Hispanic blacks had considerable differences in minor allele frequency compared with non-Hispanic whites, with almost one-quarter of variants differing by at least 20% (absolute difference). In contrast, less than 10% of variants differed by at least 20% in allele frequency between Mexican Americans and non-Hispanic whites. Differences in allele and genotype frequency could partially contribute to differences in disease occurrence between population subgroups. As an example, the Pro12Ala variant of PPARG (rs1801282) has been studied extensively in relation to type 2 diabetes, with the Pro allele (C) being associated with increased disease prevalence (50). This finding has been duplicated in some genome-wide association studies (13–15), although not in all populations (51, 52). The higher CC genotype prevalence in non-Hispanic blacks (95.0%) compared with non-Hispanic whites (75.8%) may be a strong contributing factor to the increased risk of type 2 diabetes among non-Hispanic blacks, as this PPARG variant has been estimated to have a large population attributable risk of ∼25% (50). Because differences in the occurrence of common human diseases among populations reflect variation in genetic factors, environmental factors, and their interaction, population-based genotype data, when coupled with other disease risk factors, will give us better insight into the causes of population differences in the occurrence of various diseases.

On the other hand, allele frequency and genotype prevalence did not differ significantly between men and women for most of the genetic variants studied (≥97.8%). Similar findings on allele frequency or genotype prevalence by sex have also been reported in some large studies (32, 33). Although we report statistically significant differences by age for approximately one-fifth of the genetic variants studied, most of these differences were no longer present after adjustment for race/ethnicity. This finding is likely attributable to the differences in age distribution between the race/ethnic groups (Table 1). Some of the significant differences in allele frequencies by age may indicate survival advantage, and other studies have found variants in or near MTHFR (53, 54), PON1 (55, 56), TLR4 (55, 57), and TNF (58) associated with aging or longevity. However, few genes have been reproducibly shown to do so (59, 60), and our results could be due to insufficient sample sizes or due to statistical chance in analyses.

There has been a concern that multiple individuals from a household were included (average household, 1.59 individuals; range, 1–11) in NHANES III for the estimation of allele and genotype frequencies. However, the estimates were calculated by using methods specifically designed to analyze data from surveys with complex designs. These methods adopt NHANES III sample weights and adjust the variance of the estimate among the correlated observations. NHANES III is a population-based survey that reflects the actual and overall genetic structure of the general US population, which contains many related individuals within or between subpopulations. Thus, inclusion of related individuals in the NHANES III survey should enhance the generalizability of estimates derived from these data.

Some potential limitations of this study are notable. First, NHANES III categorizes race and ethnicity according to self-reported affiliation, as do most epidemiologic studies. There is considerable literature on the accuracy of this social measure as a proxy for genetic ancestry (61–65). Despite the possible misclassification or oversimplification of genetic ancestry, these data may help to elucidate the uncertain contribution of genetic variation (65, 66) to the complex interactions among social, environmental, and behavioral influences in a diverse population that contribute to racial and ethnic health disparities. Another concern is that homozygotes were not detected for some rare polymorphisms in this study, and thus the statistical tests for these genetic variants may not be reliable. In addition, future studies of gene–disease associations and gene–environment interactions with rare variants may be limited by insufficient sample sizes when analyses are performed separately for each race/ethnic group and control for large numbers of variables.

In the near future, we plan to use race and ethnicity, as well as geographic information, to conduct a focused examination of the genetic substructure of the US population and subpopulations. This issue is generating increased interest, because latent population substructure has been discovered in populations previously thought to be relatively homogeneous (67, 68). Such analyses are, therefore, especially important for the heterogeneous US population and considering the high levels of admixture within African-American and Mexican-American populations (69–72). Multiple studies demonstrate that population substructure must be taken into account in the design and interpretation of genetic association studies (67, 68, 70, 73–75). Further research on population characteristics and genetic diversity will be invaluable in conducting genetic epidemiologic studies in the United States.

Determination of the prevalence of genetic polymorphisms associated with common diseases of public health importance in the US population and in subgroups of the population is a critical first step in evaluating the genetic epidemiology of complex diseases. These prevalence estimates can be used in predicting sample size requirements for future epidemiologic studies to evaluate genetic determinants of susceptibility to chronic and infectious diseases, the severity of disease, and interactions with other risk factors. Because data on genotype frequency are particularly sparse for non-Hispanic blacks and Mexican Americans, our estimates are useful in sample size calculations for studying the genomic contribution to the health of these populations. Investigations currently underway examine the associations of the reported genetic variants with select nutritional, biochemical, and clinical characteristics in the NHANES III data set that serve as markers or risk factors for numerous health outcomes. These outcomes include asthma and chronic obstructive pulmonary disease, diabetes, cardiovascular disease, viral infections, and osteoporosis.

With the recent successes of genome-wide association studies, the resource of the NHANES III DNA bank offers significant opportunities to move beyond investigations of candidate genes, as was done here. Many recent genome-wide association studies have uncovered replicable genetic associations with diseases such as breast (4–6), prostate (7, 9), and colorectal (8, 10) cancers; heart disease (11, 12); diabetes (13–17); and obesity (18–20). However, many of these large-scale, case-control studies did not use representative samples of the underlying populations from which the cases were derived. NHANES is the only nationally representative, population-based sample survey that systematically collects physical, physiologic, imaging, laboratory, and interview data on a large number of individuals in the United States. Use of a whole-genome approach to assess the prevalence of genetic polymorphisms, including copy number variants, in the NHANES III DNA bank will be an important next step toward identifying genetic variants that can help to predict disease susceptibility and progression. This approach will also provide the basis for estimating the numbers of people in the United States who may benefit from genome-based tools, such as risk factor reduction; disease screening efforts; or diagnostic tests, drugs, or other preventive or therapeutic interventions. Current and future NHANES III prevalence estimates will be deposited into a publicly accessible database for research.

Thus, this first effort in NHANES begins to lay a strong scientific foundation for studying the impact of genetic variation on common diseases in the United States and in the future evaluation of biomarkers and diagnostic tests. Information derived from NHANES will provide an important reference and will enhance the translation of genomic information into clinical and public health practice.

Abbreviations

    Abbreviations
  • CDC

    Centers for Disease Control and Prevention

  • CI

    confidence interval

  • NCHS

    National Center for Health Statistics

  • NCI

    National Cancer Institute

  • NHANES III

    Third National Health and Nutrition Examination Survey

  • SNP

    single nucleotide polymorphism

Author affiliations: National Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia (Man-huei Chang, Nicole F. Dowling, Ramal Moonesinghe, Renée M. Ned, Ajay Yesupriya, Muin J. Khoury); National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia (Mary Lou Lindegren, Mary R. Reichler); National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, Ohio (Mary A. Butler); National Cancer Institute, National Institutes of Health, Rockville, Maryland (Stephen J. Chanock); National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia (Margaret Gallagher); National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia (Cynthia A. Moore); National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland (Christopher L. Sanders); and Core Genotyping Facility, Division of Cancer Epidemiology and Genetics, Advanced Technology Program, SAIC Frederick, Inc., NCI-Frederick, Maryland (Robert Welch).

The authors would like to dedicate this article in memory of Bob Welch, a treasured collaborator and friend.

This work was supported by the Centers for Disease Control and Prevention, Atlanta, Georgia.

The authors would like to thank the following individuals from the CDC/NCI NHANES III Genomics Working Group: National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr. Craig Hooper, Dr. Quanhe Yang); National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr. Karon Abe, Dr. Heidi M. Blanck, Dr. Ingrid J. Hall, Dr. Guiseppina Imperatore, Dr. Ann Malarcher, Dr. Glen Satten); National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr. Amanda Brown, Dr. Omar Henderson, Dr. Deborah Koontz); National Center for Environmental Health, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia (Olivia Harris); National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr. Michael Aidoo, Dr. Robert Chen, Dr. Janet McNicholl); National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr. Venkatachalam Udhayakumar); National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, West Virginia (Dr. Ainsley Weston); National Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr. Marta Gwinn, Tiebin Liu, Dr. Wei Yu); Office of the Director, Coordinating Center for Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia (Dr. Karen Steinberg); National Cancer Institute, National Institutes of Health, Rockville, Maryland (Dr. Neil Caporaso, Amy Hutchinson); Office of the Medical Director, March of Dimes Foundation, New York, New York (Bruce Lin); Department of Medicine, University of Washington School of Medicine, Seattle, Washington (Dr. Jai Lingappa); Department of Epidemiology and Community Medicine, University of Ottawa, Ontario, Canada (Dr. Julian Little); Division of Medical Genetics, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah (Dr. Lorenzo Botto); Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia (Dr. Tom Hodge); Program in Health Decision Science, Harvard University, Cambridge, Massachusetts (Davene Wright).

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Conflict of interest: none declared.

References

1.
Lander
ES
Linton
LM
Birren
B
, et al.  . 
Initial sequencing and analysis of the human genome
Nature
 , 
2001
, vol. 
409
 
6822
(pg. 
860
-
921
)
2.
Venter
JC
Adams
MD
Myers
EW
, et al.  . 
The sequence of the human genome
Science
 , 
2001
, vol. 
291
 
5507
(pg. 
1304
-
1351
)
3.
International Human Genome Sequencing Consortium
Finishing the euchromatic sequence of the human genome
Nature
 , 
2004
, vol. 
431
 
7011
(pg. 
931
-
945
)
4.
Easton
DF
Pooley
KA
Dunning
AM
, et al.  . 
Genome-wide association study identifies novel breast cancer susceptibility loci
Nature
 , 
2007
, vol. 
447
 
7148
(pg. 
1087
-
1093
)
5.
Hunter
DJ
Kraft
P
Jacobs
KB
, et al.  . 
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
Nat Genet.
 , 
2007
, vol. 
39
 
7
(pg. 
870
-
874
)
6.
Stacey
SN
Manolescu
A
Sulem
P
, et al.  . 
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer
Nat Genet.
 , 
2007
, vol. 
39
 
7
(pg. 
865
-
869
)
7.
Gudmundsson
J
Sulem
P
Manolescu
A
, et al.  . 
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24
Nat Genet.
 , 
2007
, vol. 
39
 
5
(pg. 
631
-
637
)
8.
Tomlinson
I
Webb
E
Carvajal-Carmona
L
, et al.  . 
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21
Nat Genet.
 , 
2007
, vol. 
39
 
8
(pg. 
984
-
988
)
9.
Yeager
M
Orr
N
Hayes
RB
, et al.  . 
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
Nat Genet.
 , 
2007
, vol. 
39
 
5
(pg. 
645
-
649
)
10.
Zanke
BW
Greenwood
CM
Rangrej
J
, et al.  . 
Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24
Nat Genet.
 , 
2007
, vol. 
39
 
8
(pg. 
989
-
994
)
11.
Helgadottir
A
Thorleifsson
G
Manolescu
A
, et al.  . 
A common variant on chromosome 9p21 affects the risk of myocardial infarction
Science
 , 
2007
, vol. 
316
 
5830
(pg. 
1491
-
1493
)
12.
McPherson
R
Pertsemlidis
A
Kavaslar
N
, et al.  . 
A common allele on chromosome 9 associated with coronary heart disease
Science
 , 
2007
, vol. 
316
 
5830
(pg. 
1488
-
1491
)
13.
Zeggini
E
Weedon
MN
Lindgren
CM
, et al.  . 
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes
Science
 , 
2007
, vol. 
316
 
5829
(pg. 
1336
-
1341
)
14.
Saxena
R
Voight
BF
Lyssenko
V
, et al.  . 
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Science
 , 
2007
, vol. 
316
 
5829
(pg. 
1331
-
1336
)
15.
Scott
LJ
Mohlke
KL
Bonnycastle
LL
, et al.  . 
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Science
 , 
2007
, vol. 
316
 
5829
(pg. 
1341
-
1345
)
16.
Hakonarson
H
Grant
SF
Bradfield
JP
, et al.  . 
A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene
Nature
 , 
2007
, vol. 
448
 
7153
(pg. 
591
-
594
)
17.
Todd
JA
Walker
NM
Cooper
JD
, et al.  . 
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
Nat Genet.
 , 
2007
, vol. 
39
 
7
(pg. 
857
-
864
)
18.
Herbert
A
Gerry
NP
McQueen
MB
, et al.  . 
A common genetic variant is associated with adult and childhood obesity
Science
 , 
2006
, vol. 
312
 
5771
(pg. 
279
-
283
)
19.
Frayling
TM
Timpson
NJ
Weedon
MN
, et al.  . 
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity
Science
 , 
2007
, vol. 
316
 
5826
(pg. 
889
-
894
)
20.
Scuteri
A
Sanna
S
Chen
WM
, et al.  . 
Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits
PLoS Genet.
 , 
2007
, vol. 
3
 
7
pg. 
e115
 
21.
The International HapMap Consortium
The International HapMap Project
Nature
 , 
2003
, vol. 
426
 
6968
(pg. 
789
-
796
)
22.
The International HapMap Consortium
A haplotype map of the human genome
Nature
 , 
2005
, vol. 
437
 
7063
(pg. 
1299
-
1320
)
23.
The International HapMap Consortium
Frazer
KA
Ballinger
DG
, et al.  . 
A second generation human haplotype map of over 3.1 million SNPs
Nature
 , 
2007
, vol. 
449
 
7164
(pg. 
851
-
861
)
24.
Feuk
L
Carson
AR
Scherer
SW
Structural variation in the human genome
Nat Rev Genet.
 , 
2006
, vol. 
7
 
2
(pg. 
85
-
97
)
25.
Redon
R
Ishikawa
S
Fitch
KR
, et al.  . 
Global variation in copy number in the human genome
Nature
 , 
2006
, vol. 
444
 
7118
(pg. 
444
-
454
)
26.
Khaja
R
Zhang
J
MacDonald
JR
, et al.  . 
Genome assembly comparison identifies structural variants in the human genome
Nat Genet.
 , 
2006
, vol. 
38
 
12
(pg. 
1413
-
1418
)
27.
Korbel
JO
Urban
AE
Affourtit
JP
, et al.  . 
Paired-end mapping reveals extensive structural variation in the human genome
Science
 , 
2007
, vol. 
318
 
5849
(pg. 
420
-
426
)
28.
Lin
BK
Clyne
M
Walsh
M
, et al.  . 
Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database
Am J Epidemiol
 , 
2006
, vol. 
164
 
1
(pg. 
1
-
4
)
29.
Hirschhorn
JN
Lohmueller
K
Byrne
E
, et al.  . 
A comprehensive review of genetic association studies
Genet Med
 , 
2002
, vol. 
4
 
2
(pg. 
45
-
61
)
30.
Ioannidis
JP
Ntzani
EE
Trikalinos
TA
, et al.  . 
Replication validity of genetic association studies
Nat Genet.
 , 
2001
, vol. 
29
 
3
(pg. 
306
-
309
)
31.
Little
J
Bradley
L
Bray
MS
, et al.  . 
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations
Am J Epidemiol
 , 
2002
, vol. 
156
 
4
(pg. 
300
-
310
)
32.
Garte
S
Gaspari
L
Alexandrie
AK
, et al.  . 
Metabolic gene polymorphism frequencies in control populations
Cancer Epidemiol Biomarkers Prev
 , 
2001
, vol. 
10
 
12
(pg. 
1239
-
1248
)
33.
Huang
HY
Thuita
L
Strickland
P
, et al.  . 
Frequencies of single nucleotide polymorphisms in genes regulating inflammatory responses in a community-based population
BMC Genet.
 , 
2007
, vol. 
8
 pg. 
7
 
34.
National Center for Health Statistics, Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey
2007
Hyattsville, MD
National Center for Health Statistics
 
(http://www.cdc.gov/nchs/nhanes.htm). (Accessed March 4, 2008)
35.
National Center for Health Statistics
Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988–94
 , 
1994
Hyattsville, MD
National Center for Health Statistics
 
(Vital and Health Statistics, Series 1: Programs and Collection Procedures, no. 32) (DHHS publication no. (PHS) 94-1308) (GPO no. 017-022-01260-0). (http://www.cdc.gov/nchs/data/series/sr_01/sr01_032.pdf)
36.
Agency for Healthcare Research and Quality, US Department of Health and Human Services
National Healthcare Disparities Report, 2006
 , 
2007
Rockville, MD
Agency for Healthcare Research and Quality
 
(http://www.ahrq.gov/qual/nhdr06/nhdr06.htm). (Accessed March 4, 2008)
37.
Jemal
A
Siegel
R
Ward
E
, et al.  . 
Cancer statistics, 2006
CA Cancer J Clin
 , 
2006
, vol. 
56
 
2
(pg. 
106
-
130
)
38.
Health disparities experienced by Hispanics—United States
MMWR Morb Mortal Wkly Rep
 , 
2004
, vol. 
53
 
40
(pg. 
935
-
937
)
39.
Health disparities experienced by black or African Americans—United States
MMWR Morb Mortal Wkly Rep
 , 
2005
, vol. 
54
 
1
(pg. 
1
-
3
)
40.
Cowie
CC
Rust
KF
Byrd-Holt
DD
, et al.  . 
Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002
Diabetes Care
 , 
2006
, vol. 
29
 
6
(pg. 
1263
-
1268
)
41.
Olden
K
White
SL
Health-related disparities: influence of environmental factors
Med Clin North Am.
 , 
2005
, vol. 
89
 
4
(pg. 
721
-
738
)
42.
Barnes
KC
Genetic epidemiology of health disparities in allergy and clinical immunology
J Allergy Clin Immunol
 , 
2006
, vol. 
117
 
2
(pg. 
243
-
254
quiz 255–256
43.
National Center for Health Statistics, Centers for Disease Control and Prevention. Third National Health and Nutrition Examination Survey (NHANES III) data files
2007
Hyattsville, MD
National Center for Health Statistics
 
44.
National Center for Health Statistics, Centers for Disease Control and Prevention. NHANES III genetic data
2007
Hyattsville, MD
National Center for Health Statistics
 
45.
Packer
BR
Yeager
M
Burdett
L
, et al.  . 
SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes
Nucleic Acids Res.
 , 
2006
, vol. 
34
 
Database issue
(pg. 
D617
-
D621
)
46.
Trikalinos
TA
Salanti
G
Khoury
MJ
, et al.  . 
Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations
Am J Epidemiol
 , 
2006
, vol. 
163
 
4
(pg. 
300
-
309
)
47.
Lohr
SL
 
Sampling: Design and Analysis. 1st ed. Pacific Grove, CA: Duxbury Press, Publisher; 1999
48.
Binder
D
On the variance of asymptotically normal estimators from complex surveys
Int Stat Rev.
 , 
1983
, vol. 
51
 (pg. 
279
-
292
)
49.
Woodruff
R
A simple method for approximating the variance of a complicated estimate
J Am Stat Assoc.
 , 
1971
, vol. 
66
 (pg. 
411
-
414
)
50.
Altshuler
D
Hirschhorn
JN
Klannemark
M
, et al.  . 
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
Nat Genet.
 , 
2000
, vol. 
26
 
1
(pg. 
76
-
80
)
51.
Hayes
MG
Pluzhnikov
A
Miyake
K
, et al.  . 
Identification of type 2 diabetes genes in Mexican Americans through genome-wide association studies
Diabetes
 , 
2007
, vol. 
56
 
12
(pg. 
3033
-
3044
)
52.
Meigs
JB
Manning
AK
Fox
CS
, et al.  . 
Genome-wide association with diabetes-related traits in the Framingham Heart Study
BMC Med Genet.
 , 
2007
, vol. 
8
 
suppl 1
pg. 
S16
 
53.
Kluijtmans
LA
Whitehead
AS
Reduced frequency of the thermolabile methylenetetrahydrofolate reductase genotype in the elderly
Atherosclerosis
 , 
1999
, vol. 
146
 
2
(pg. 
395
-
397
)
54.
Stessman
J
Maaravi
Y
Hammerman-Rozenberg
R
, et al.  . 
Candidate genes associated with ageing and life expectancy in the Jerusalem longitudinal study
Mech Ageing Dev.
 , 
2005
, vol. 
126
 
2
(pg. 
333
-
339
)
55.
Lunetta
KL
D'Agostino
RB
Sr
Karasik
D
, et al.  . 
Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study
BMC Med Genet.
 , 
2007
, vol. 
8
 
suppl 1
pg. 
S13
 
56.
Rea
IM
McKeown
PP
McMaster
D
, et al.  . 
Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis
Exp Gerontol
 , 
2004
, vol. 
39
 
4
(pg. 
629
-
635
)
57.
Balistreri
CR
Candore
G
Colonna-Romano
G
, et al.  . 
Role of Toll-like receptor 4 in acute myocardial infarction and longevity
JAMA
 , 
2004
, vol. 
292
 
19
(pg. 
2339
-
2340
)
58.
Soto-Vega
E
Richaud-Patin
Y
Llorente
L
Human leukocyte antigen class I, class II, and tumor necrosis factor-alpha polymorphisms in a healthy elder Mexican Mestizo population
Immun Ageing
 , 
2005
, vol. 
2
 pg. 
13
 
59.
Christensen
K
Johnson
TE
Vaupel
JW
The quest for genetic determinants of human longevity: challenges and insights
Nat Rev Genet.
 , 
2006
, vol. 
7
 
6
(pg. 
436
-
448
)
60.
Capri
M
Salvioli
S
Sevini
F
, et al.  . 
The genetics of human longevity
Ann N Y Acad Sci.
 , 
2006
, vol. 
1067
 (pg. 
252
-
263
)
61.
Foster
MW
Sharp
RR
Beyond race: towards a whole-genome perspective on human populations and genetic variation
Nat Rev Genet.
 , 
2004
, vol. 
5
 
10
(pg. 
790
-
796
)
62.
Jorde
LB
Wooding
SP
Genetic variation, classification and ‘race’
Nat Genet.
 , 
2004
, vol. 
36
 
11 suppl
(pg. 
S28
-
S33
)
63.
Risch
N
Burchard
E
Ziv
E
, et al.  . 
Categorization of humans in biomedical research: genes, race and disease
Genome Biol.
 , 
2002
, vol. 
3
  
comment2007.1–comment2007.12
64.
Bamshad
M
Wooding
S
Salisbury
BA
, et al.  . 
Deconstructing the relationship between genetics and race
Nat Rev Genet.
 , 
2004
, vol. 
5
 
8
(pg. 
598
-
609
)
65.
Bamshad
M
Genetic influences on health: does race matter?
JAMA
 , 
2005
, vol. 
294
 
8
(pg. 
937
-
946
)
66.
Collins
FS
What we do and don't know about ‘race’, ‘ethnicity’, genetics and health at the dawn of the genome era
Nat Genet.
 , 
2004
, vol. 
36
 
11 suppl
(pg. 
S13
-
S15
)
67.
Helgason
A
Yngvadottir
B
Hrafnkelsson
B
, et al.  . 
An Icelandic example of the impact of population structure on association studies
Nat Genet.
 , 
2005
, vol. 
37
 
1
(pg. 
90
-
95
)
68.
Feder
J
Ovadia
O
Glaser
B
, et al.  . 
Ashkenazi Jewish mtDNA haplogroup distribution varies among distinct subpopulations: lessons of population substructure in a closed group
Eur J Hum Genet.
 , 
2007
, vol. 
15
 
4
(pg. 
498
-
500
)
69.
Barnholtz-Sloan
JS
Chakraborty
R
Sellers
TA
, et al.  . 
Examining population stratification via individual ancestry estimates versus self-reported race
Cancer Epidemiol Biomarkers Prev
 , 
2005
, vol. 
14
 
6
(pg. 
1545
-
1551
)
70.
Choudhry
S
Coyle
NE
Tang
H
, et al.  . 
Population stratification confounds genetic association studies among Latinos
Hum Genet.
 , 
2006
, vol. 
118
 
5
(pg. 
652
-
664
)
71.
Collins-Schramm
HE
Chima
B
Morii
T
Mexican American ancestry-informative markers: examination of population structure and marker characteristics in European Americans, Mexican Americans, Amerindians and Asians
Hum Genet.
 , 
2004
, vol. 
114
 
3
(pg. 
263
-
271
)
72.
Shriver
MD
Parra
EJ
Dios
S
, et al.  . 
Skin pigmentation, biogeographical ancestry and admixture mapping
Hum Genet.
 , 
2003
, vol. 
112
 
4
(pg. 
387
-
399
)
73.
Ferreiros-Vidal
I
D'Alfonso
S
Papasteriades
C
, et al.  . 
Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe
Genes Immun
 , 
2007
, vol. 
8
 
2
(pg. 
138
-
146
)
74.
Freedman
ML
Reich
D
Penney
KL
, et al.  . 
Assessing the impact of population stratification on genetic association studies
Nat Genet.
 , 
2004
, vol. 
36
 
4
(pg. 
388
-
393
)
75.
Marchini
J
Cardon
LR
Phillips
MS
, et al.  . 
The effects of human population structure on large genetic association studies
Nat Genet.
 , 
2004
, vol. 
36
 
5
(pg. 
512
-
517
)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.